Pompe Disease Market Report 2026

The pompe disease market size has grown strongly in recent years. It will grow from $1.8 billion in 2025 to $1.91 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to improved newborn screening programs, availability of approved ERT treatments, increased awareness of rare genetic disorders, expansion of genetic testing capabilities, growth of specialty care centers.

The pompe disease market size is expected to see strong growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising investments in gene and cell therapies, increasing research on next-generation ERTs, expansion of personalized medicine approaches, growing access to rare disease diagnostics, increasing focus on early intervention strategies. Major trends in the forecast period include increasing adoption of enzyme replacement therapy, rising focus on early genetic screening, growing development of gene therapy approaches, expansion of specialized treatment centers, enhanced long-term disease management.

The increase in healthcare expenditure is expected to drive the growth of the Pompe disease market going forward. Healthcare expenditure refers to the financial resources invested by governments, insurers, and private organizations to enhance medical services, strengthen diagnostic infrastructure, and broaden access to treatments. The need for higher healthcare spending is rising as healthcare systems place greater emphasis on early diagnosis, management of rare diseases, and improved patient outcomes. Increased investment supports the wider adoption of enzyme replacement therapies and the development of emerging treatment innovations, enabling better disease management and improving quality of life for individuals with Pompe disease. For instance, in May 2023, according to the Office for National Statistics, a UK-based government department, healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared with growth of 0.9% in 2022. Total healthcare expenditure in the UK was approximately $317.63 billion (£292 billion) in 2023. Therefore, rising healthcare expenditure is contributing to the growth of the Pompe disease market.

Major companies operating in the Pompe disease market are focusing on advancing investigational therapies through strategic partnerships to accelerate product development, expand global reach, and strengthen treatment pipelines. Strategic partnerships involve collaborative arrangements in which organizations combine expertise, resources, and capabilities to achieve shared objectives. For instance, in June 2024, Shionogi & Company, Limited, a Japan-based pharmaceutical company, entered into a global licensing agreement with Maze Therapeutics, a US-based biotechnology company, for MZE001, an investigational oral therapy for Pompe disease. Under the agreement, Shionogi obtained exclusive global rights to MZE001 and its associated intellectual property in exchange for an upfront payment of $150 million, along with potential milestone and royalty payments. The deal was completed following the mandatory 30-day review period under US antitrust regulations.

In May 2024, Maze Therapeutics, a US-based biotechnology company developing treatments for Pompe disease, partnered with Shionogi & Co., Ltd. to further develop MZE001, a first-in-class oral therapy candidate for Pompe disease. Through this partnership, Shionogi received global rights to develop and commercialize MZE001, which is currently undergoing Phase 1 clinical trials. Shionogi & Co., Ltd. is a Japan-based pharmaceutical company engaged in drug development, manufacturing, and the commercialization of innovative therapeutic solutions.

Major companies operating in the pompe disease market are Sanofi S.A., Genzyme Corporation, Amicus Therapeutics Inc., BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Valerion Therapeutics LLC, Protalix BioTherapeutics, AVROBIO Inc., Abeona Therapeutics Inc., Sangamo BioSciences Inc., Asklepios BioPharmaceutical Inc., Audentes Therapeutics Inc., Genethon, Akashi Therapeutics, M6P Therapeutics, Aro Biotherapeutics Company, Avidity Biosciences Inc., Maze Therapeutics Inc., Novartis AG, F. Hoffmann-La Roche AG, Spark Therapeutics Inc., REGENXBIO Inc.

North America was the largest region in the pompe disease market in 2025. The regions covered in the pompe disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pompe disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the pompe disease market by increasing costs of imported biologics, recombinant enzymes, gene therapy vectors, and specialized laboratory equipment. North America and Europe are most affected due to dependence on advanced biologic manufacturing inputs, while Asia-Pacific faces higher costs for exporting rare disease therapies. These tariffs are elevating treatment prices and affecting patient access. However, they are also encouraging localized biologics production, regional clinical research, and strengthened domestic capabilities for rare disease drug development.

The pompe disease market research report is one of a series of new reports that provides pompe disease market statistics, including pompe disease industry global market size, regional shares, competitors with a pompe disease market share, detailed pompe disease market segments, market trends and opportunities, and any further data you may need to thrive in the pompe disease industry. This pompe disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pompe disease is a genetic disorder in which a complex sugar known as glycogen builds up within the body’s cells. This condition occurs due to a deficiency of the enzyme acid alfa glucosidase (GAA), which is responsible for breaking down complex carbohydrates in the body.

The main forms of Pompe disease include the classic infantile form, non classic infantile form, late onset form, and others. The classic infantile form is the most widely recognized type and is characterized by severe cardiac dysfunction and marked hypotonia that typically begins within the first few months of life. Diagnostic approaches for Pompe disease include blood tests, genetic testing, prenatal testing, and other diagnostic methods. Treatment options include oral, parenteral, and other approaches. Therapies used for Pompe disease include enzyme replacement therapy, substrate reduction therapy, gene therapy, and others, and these are utilized by hospitals or clinics, pharmaceutical companies, research institutions, and other end users.

The pompe disease market includes revenues earned by entities by lumizyme, alglucosidase alfa, nexviazyme, and aval glucosidase alfa. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.